Assessment of EPS and tardive dyskinesia in clinical trials

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 12, 1998, Pages 23-27

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AKATHISIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG CHOICE; DRUG SAFETY; DYSTONIA; HUMAN; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; REVIEW; TARDIVE DYSKINESIA;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CLINICAL TRIALS; CLOZAPINE; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; DYSTONIA; HUMANS; PARKINSON DISEASE, SECONDARY; PIRENZEPINE; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0031698105     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
2. Beasley CM Jr, Tollefson GD, Tran PV, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
3. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
4. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
5. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124(1-2):168-175
6. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl 10):55-62
7. Remington G, Kapur S. Neuroleptic-induced extrapyramidal symptoms and the role of combined serotonin/dopamine antagonism. J Clin Psychiatry Monograph 1996;14(1):14-24
8. Grebb JA. General principles of psychopharmacology. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, vol 2. 6th ed. Baltimore, Md: Williams & Wilkins; 1995:1912
9. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55(9, suppl B):107-109
10. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15 (suppl 1):36S-44S
11. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406
12. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73
13. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96
14. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J Pharmacol Exp Ther 1989;251:238-246
15. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benztropine. Arch Gen Psychiatry 1988;45:789-796
16. Bennett JP Jr, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43: 1551-1555
17. Peuskens J and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
18. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter place-bo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
19. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308-313
20. Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 1997;12(suppl 4):S3-S10
21. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
22. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1998
23. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-211
24. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154: 1248-1254
25. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
26. Arvanitis LA, Miller BG and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
27. Marder SR. Clinical experience with risperidone. J Clin Psychiatry 1996; 57(suppl 9):57-61